Summary & Overview
HCPCS S9359: Home Infusion Anti‑TNF Administrative and Pharmacy Services
HCPCS Level II code S9359 designates a per diem administrative and professional pharmacy services bundle for home infusion of anti-tumor necrosis factor intravenous therapies (for example, infliximab). The code is used to capture non-drug components of home-based biologic infusion care — including pharmacy administration coordination, supplies, and equipment — while the medication and nursing visits are billed separately. This distinction matters as home infusion programs for biologics expand and payers refine coverage and payment policies for site-neutral care.
Key payers referenced in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what S9359 represents clinically and operationally, how it fits into home infusion billing workflows, and what components are excluded (notably drug and nursing visit charges). The publication provides national-level benchmarks and coverage context where available, highlights relevant policy updates affecting home infusion reimbursement, and summarizes clinical considerations for anti-TNF intravenous therapy in the home setting.
Data not available in the input: associated taxonomies, specific ICD-10 diagnoses, related codes, and payer-specific price benchmarks.
Billing Code Overview
HCPCS Level II code S9359 describes home infusion therapy for anti-tumor necrosis factor (anti-TNF) intravenous therapy, for example, infliximab. The code is intended to capture per diem administrative services associated with home-based infusion, including professional pharmacy services, care coordination, and necessary supplies and equipment. Drugs and nursing visits are billed separately and are not included in this per diem service.
Service type: Home infusion administrative and professional pharmacy services
Typical site of service: Patient's home (home infusion setting)
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old with moderate to severe Crohn disease receiving maintenance intravenous infliximab at home. The patient has a stable vascular access (peripheral IV or PICC) and requires per diem home infusion services covering administrative oversight, professional pharmacy services, care coordination, and supplies; the biologic drug and any nursing visits are billed separately. The clinical workflow begins with the prescribing clinician documenting the indication and dosing schedule, the pharmacy verifying the prescription and preparing the infusion drug, and the home infusion provider coordinating a scheduled home visit. Prior to each infusion day the pharmacist performs order verification and stability checks, the nurse confirms patient identity, reviews allergies/contraindications, assesses vital signs and infusion site, and initiates infusion per protocol. The infusion is monitored for infusion-related reactions; emergency protocols are in place with direct communication to the ordering clinician. Documentation includes medication administration record, infusion start/stop times, patient tolerance, and any adverse events. Per diem billing using S9359 covers administrative and pharmacy professional services, care coordination, and supplies/equipment; the actual biologic agent (e.g., infliximab) and separate nursing visit charges are reported with their appropriate drug and professional codes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |